Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

‘Repurposed’ NHS drug could help prevent thousands of women from breast cancer

The drug can 'reduce' breast cancer incidence in post-menopausal women by almost 50 per cent

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Anastrozole in a new use to prevent the disease.


The off-patent drug has been used as a breast cancer treatment for many years.

Clinical trials have shown that it can reduce the incidence of breast cancer in post-menopausal women with increased risk by almost 50 per cent.

Health Minister Will Quince expressed his happiness on the approval of the drug that can help to prevent this "cruel disease".

He said: “We’ve already seen the positive effect Anastrozole can have in treating the disease when it has been detected in post-menopausal women and now we can use it to stop it developing at all in some women.

“This is a great example of NHS England’s innovative Medicines Repurposing Programme supporting the development of new ways for NHS patients to benefit from existing treatments.”

Dame June Raine, Chief Executive of the MHRA, said the agency welcomes applications for "repurposed medicines" and encourages early dialogue from companies or developers considering this.

In 2017, the National Institute for Health and Care Excellence first recommended it as a preventive option for breast cancer.

However, the uptake has remained low, due to a lack of licensing for preventive use.

The credit goes to a pioneering Medicines Repurposing Programme led by the National Health System (NHS) England.

According to NHS England, around 289,000 women at moderate or high risk of breast cancer could be eligible for the ‘repurposed’ drug.

It is estimated that if 25 per cent of them choose to take it, around 2,000 breast cancer cases could be prevented.

This will also help the NHS save around £15 million in treatment costs, NHS confirmed.

Amanda Pritchard, the CEO of NHS England, said: “It’s fantastic that this vital risk-reducing option could now help thousands of women and their families avoid the distress of a breast cancer diagnosis.

“Allowing more women to live healthier lives, free of breast cancer is truly remarkable, and we hope that licensing anastrozole for a new use today represents the first step to ensuring this risk-reducing option can be accessed by all who could benefit from it.”

How the breast cancer drug works  

Anastrozole is an aromatase inhibitor that helps reduce the amount of the hormone oestrogen in the patient’s body by blocking an enzyme called ‘aromatase’.

The approved dosage is recommended to 1 mg tablet once a day for five years.

The medicine can cause side effects such as hot flashes, feeling weak, pain/stiffness in the joints, arthritis, skin rash, nausea, headache, osteoporosis, and depression.

Breast cancer is the most common cancer in England, with 47,000 new cases reported each year.

More For You

A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less
Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Patients to get test results via NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

Keep ReadingShow less
Health minister assures House of Lords on measures to tackle UK-wide Creon drug shortage

Baroness Merron

Government taking steps to mitigate shortage of cancer drug Creon

Baroness Merron on Monday (9) assured the House of Lords that the government is taking measures to mitigate the shortage of pancreatic cancer drug Creon across the country.

Raising the issue, Baroness Margaret Ritchie wanted to know about the steps being taken by the government to ease the misery of patients suffering from pancreatic cancer.

Keep ReadingShow less
Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Janet Morrison

Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Community Pharmacy England (CPE) chief executive Janet Morrison has welcomed chancellor Rachel Reeves announcement today that day-to-day spending on the NHS will increase by £29bn a year but insisted that it must reflect in securing the future of pharmacy.

Reeves also revealed that the government will be increasing the NHS technology budget by almost 50 per cent, with £10bn of investment to "bring our analogue health system into the digital age, including through the NHS app".

Keep ReadingShow less
Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less